

**Drug Utilization Review Board
Minutes Draft**

Name of Meeting: Drug Utilization Review Board
Date of Meeting: September 24, 2026
Length of Meeting: 1 hour and 1 minute
Location of Meeting: DMAS Board Room 102

Members Present:

Rachel Cain, PharmD, Chair
Elizabeth Gaughan, MD, Vice-Chair
Brian Trentler, RPh
Jack Weisskohl, NP
Melissa Chouinard, MD
Michele Thomas, PharmD

Members Not Present:

Denese Gomes, NP
Denise Lowe, PharmD
Elizabeth Krieger, MD
Seth Brant, MD
Tana Kaefer, PharmD

DMAS Attendees:

Arielle Abbate, PharmD, Compliance Pharmacist
Brittany L. Olmstead, CPhT, SHRM-CP, VCARM, Pharmacy Systems Administrator

Contractors:

Nancy Eldin, PharmD, Clinical Account Principal, Prime Therapeutics
Matthew Estes, PharmD, Clinical Account Principal, Prime Therapeutics
Jeni Hodzic, CPhT, Senior Account Management Specialist, Prime Therapeutics

Guests:

8 representatives from pharmaceutical companies, providers, advocates, associations, etc.

Call to Order and Introductions

Dr. Rachel Cain welcomed and thanked everyone for attending the DUR meeting.

Dr. Cain called the DUR meeting to order at 1:11 pm.

Because a quorum of DUR Board members was not present, the Board reviewed only materials that did not require a vote. Discussion of materials requiring Board action was deferred until the December 10, 2026, DUR meeting.

Minutes – June 11, 2026

Review and approval of the June 11, 2026, meeting minutes was tabled until the December 10, 2026, DUR meeting.

Traditional DUR Drugs

The Board deferred its review of the four traditional DUR drugs and approval of the associated criteria until the December 10, 2026, DUR meeting: Baxfendy™, Hepcludex®, Veppanu™, and Zycubo®.

Physician Administered Drugs (PADs)

The Board deferred its review of Otarmeni™, a physician-administered drug, and approval of the associated criteria until the December 10, 2026, DUR meeting.

Topics for Discussion

Antipsychotic Medications in Children – The DUR Board reviewed reports on antipsychotic medication use among children in both the FFS and MCO populations.

Antidepressant Medications in Children – The DUR Board reviewed reports on antidepressant medication use among children in both the FFS and MCO populations. The Board requested that rate-based percentages be included in all reports. A Board member also asked whether medication adherence could be evaluated; this will be researched for potential inclusion in future reports.

Mood Stabilizer Medications in Children – The DUR Board reviewed reports on mood stabilizer medication use among children in both the FFS and MCO populations.

Anti-anxiety or Sedative Medications in Children – The DUR Board reviewed reports on anti-anxiety or sedative medication use among children in both the FFS and MCO populations.

Overlaps in Antipsychotics, Antidepressants, Mood Stabilizers and Anti-anxiety or Sedatives in Children – The DUR Board reviewed reports examining the concurrent use of antipsychotic, antidepressant, mood stabilizer, and anti-anxiety or sedative medications among children in both the FFS and MCO populations.

Antipsychotic Medications in Adults Receiving Home or Community-Based Services or Residing in Institutional Care Settings, such as Nursing Homes – The DUR Board reviewed a new report on antipsychotic medication use among adults receiving home- and community-based services or residing in institutional care settings, including nursing homes, across the FFS and MCO populations. For future reports, the Board requested stratification by age group and a detailed review of more than five FFS members. DMAS and Prime will also conduct a detailed internal review of all identified FFS members.

Leucovorin Trend Analysis – The DUR Board reviewed new reports evaluating leucovorin utilization trends in the FFS and MCO populations. The Board requested additional clinical context and supporting evidence regarding current leucovorin uses, along with input from an appropriate specialist, such as a pediatrician, psychiatrist, or neurologist. The topic will be presented again at the December 10, 2026, DUR meeting with the requested information.

DUR Quarterly Newsletter - The June 2026 DUR Quarterly Newsletter was included in the DUR binder for review.

Prime Therapeutics Pipeline – The DUR Board reviewed the following four pipeline drugs: oral brepocitinib, oral ribitol (BBP-418), subcutaneous rusfertide, and oral tiratricol (Emcite).

Reports

ProDUR

The DUR Board reviewed and discussed the ProDUR reports.

RetroDUR

I. Recent RetroDUR Activity

The DUR Board reviewed the Recent RetroDUR Activity reports.

II. RetroDUR Criteria Estimates

The Criteria Exception Estimates reports were included in the DUR binder for review. For the FFS population and each individual MCO plan, the reports presented the top 40 criteria exceptions by number of members and by total payment amount.

The DUR Board requested that the criterion identifying members with type 2 diabetes and heart failure (HF) or coronary artery disease (CAD) who had no claims for sodium-glucose cotransporter-2 (SGLT2) inhibitors be expanded to include chronic kidney disease (CKD).

Utilization Analysis

The DUR Board reviewed the Utilization Analysis reports. The board had previously requested to identify and label the preferred and non-preferred drugs on the Top 25 Drugs Ranked reports. Preferred drugs were shown in red and non-preferred drugs were shown in green.

Next DUR Meetings

- December 10, 2026 (virtual meeting)

Meeting adjourned at 2:12 pm